Oncology – Bone and Sarcomas | Links Medicus Content Curation & Alerts in Medicine

RCT | Ganitumab added to chemotherapy did not improve outcomes in patients with metastatic Ewing sarcoma

30 Mar, 2023 | 14:16h | UTC

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children’s Oncology Group – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma – Cancer Therapy Advisor

RCT | Nirogacestat for desmoid tumors

15 Mar, 2023 | 14:57h | UTC

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Nirogacestat Improves Outcomes for Patients With Desmoid Tumors – Memorial Sloan Kettering Cancer Center

Commentary on Twitter

In a randomized, placebo-controlled trial, oral nirogacestat twice daily led to 41% of patients having a tumor response, and 2-year progression-free survival was 76%. Most adverse events were low grade. https://t.co/wtt7solTHW pic.twitter.com/qkRchfnXU2

— NEJM (@NEJM) March 10, 2023

Consensus Recommendations | Spinal tumors

9 Mar, 2023 | 14:15h | UTC

Spinal tumours: recommendations of the Polish Society of Spine Surgery, the Polish Society of Oncology, the Polish Society of Neurosurgeons, the Polish Society of Oncologic Surgery, the Polish Society of Oncologic Radiotherapy, and the Polish Society of Orthopaedics and Traumatology – European Spine Journal

Review | Morbidity and mortality after surgery for retroperitoneal sarcoma

28 Feb, 2023 | 13:35h | UTC

Morbidity and Mortality after Surgery for Retroperitoneal Sarcoma – Current Oncology

German Guidelines on Sarcoma of the Uterus.

6 Dec, 2022 | 13:50h | UTC

Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021) – Geburtshilfe und Frauenheilkunde

Single-arm P2 study | Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas.

9 Nov, 2022 | 12:24h | UTC

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma – The University of Texas MD Anderson Cancer Center

RCT | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma.

9 Nov, 2022 | 12:12h | UTC

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.

8 Nov, 2022 | 12:00h | UTC

Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials – Frontiers in Oncology

Single-arm phase 2 study | Activity of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.

22 Aug, 2022 | 11:53h | UTC

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) – JAMA Oncology (free for a limited period)

Invited Commentary: Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet? – JAMA Oncology (free for a limited period)

Single-center phase 2 trial | Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas.

11 Aug, 2022 | 11:52h | UTC

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

Online first: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK pic.twitter.com/BP7fz9FWRw

— The Lancet Oncology (@TheLancetOncol) August 5, 2022

RCT | Doxorubicin alone vs. doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma.

20 Jul, 2022 | 11:36h | UTC

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

RCT: Efficacy and safety of TRC105 plus pazopanib vs. pazopanib alone for treatment of patients with advanced angiosarcoma.

27 May, 2022 | 11:15h | UTC

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial – JAMA Oncology

Commentaries:

Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post

Carotuximab addition to pazopanib does not improve survival in advanced angiosarcoma patients – Physician’s Weekly

Commentaries on Twitter

A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx

— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022

First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2

— JAMA Oncology (@JAMAOnc) March 31, 2022

RCT: Selinexor in advanced, metastatic dedifferentiated liposarcoma.

12 Apr, 2022 | 08:24h | UTC

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial – Journal of Clinical Oncology

Guidelines for diagnosing incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS).

4 Apr, 2022 | 00:45h | UTC

Society of Skeletal Radiology– white paper. Guidelines for the diagnostic management of incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS) – Skeletal Radiology

Commentary on Twitter (article and images under a http://creativecommons.org/licenses/by-nc/4.0/)

Bone RADS- White Paper from @SkeletalRadiol
Want to know how to handle bone lesions? Take a look – open access:https://t.co/mBUFzgJiCf @cychang1414 @ahlawat_shivani @HillaryGarnerMD @mbucknor @Radsdoc82 @behrangamini @IKhodarahmi @JimWuMSK
Apologies couldn't find all authors pic.twitter.com/hL8r04uK40

— Adam Singer, MD (@AdamSingerMD) April 1, 2022